GSK reports positive results from ovarian cancer drug trial
has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of progression free survival.
Headline results from the FIRST-ENGOT-OV44 phase III trial evaluating a combination of Zejula (niraparib) and Jemperli (dostarlimab) showed statistically significant difference compared with standard-of-care chemotherapy.
Standard-of-care platinum-based chemotherapy have high response rates, but around 85% of patients will experience disease recurrence, GSK said. Once the disease recurs, it is rarely curable.
"As part of our focus in gynaecological cancers, we continue to evaluate the potential of this combination and look forward to sharing full results from the trial," said Hesham Abdullah, senior vice president, global head oncology, at GSK's R&D division.
However, the secondary endpoint did not meet statistical significance. GSK said that further analyses are ongoing and data will be shared with health authorities.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.